Tumor-Specific Cancer Vaccine Adjuvant Formulation



    • Many cancer vaccines fail due to insufficient CD8+ T cell targeting.  To save patient lives, oncologists need tumor-specific vaccines that increase CD8+ T cell response.
    • The inventors developed and validated an intra-tumoral vaccine adjuvant for muringe melanoma.  They used a p(ManTLR7) glyco-polymer to chemically link to tumor cell binding moieties (i.e., (f(ab)2, fAb, scFv, etc.).  Their adjuvant conjugation Anti-p(Man-TLR7) augmented tissue localization and biodistribution.
    • Anti-p(Man-TLR7) builds on earlier use of p(Man-TLR7) as a priming agent for strong CD8+ T cell responses to traditional model antigens and malaria vaccination models.
    • The team's in vivo experiments with B16F10 tumor-bearing mice demonstrated that Anti-p(ManTLR7) outperforms CpG, a TLR9 stimulating adjuvant, for tumor size reduction and survival rate.


    A) Mice tissue retains anti-TRP1-pManTLR7 intratumorally. During imaging studies, 30μg of fluorescently labeled anti-TRP1- pManTLR7 were injected intratumorally 5 days after B16F10 tumor inoculation (4x105 cells).  Tumor growth slowed significantly.  B) Anti-TRP1-pManTLR7 treatment reduces B16F10 melanoma growth rates, systemic exposure to TLR7 and overall death rates.  Note that 50% of all Anti-TRP1-pManTLR7 treated mice survived to Day 20.  No mice who received unconjugated treatment, on the other hand, were alive on 20.



    • The tumor serves as a source of antigen to which immune responses are generated.
    • Based on CpG's track record, this approach is scalable from melanoma to breast cancer, colon cancer, glioblastoma, lymphoma, sarcoma, and ovarian cancer.
    • Anti-TRP1-pManTLR7 exhibits low potential for off-target effects and overall tolerability.


    • Monotherapy
    • Immune checkpoint inhibitors


    • Iteration of Hubbell Lab Patent WO2017058996A1



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.